Lexeo Therapeutics LXEO LXEO Granted Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy罕见病
发布于: | Android | 转发:0 | 回复:0 | 喜欢:0 |
Lexeo Therapeutics LXEO LXEO Granted Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy罕见病